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COMPARISON of the uptake of 17 different radioactive substances by brain and
tumour in rats has shown that in these tumours 95Nb oxalate is taken up in higher
concentration than any other isotope investigated (Matthews and Molinaro, 1963).
The distribution and metabolism ofthis isotope in tissues has been further examined
in an attempt to improve tumour uptake sufficiently to enable it to be used in
diagnosis.
One possibility might be to label fibrinogen with 95Nb, since there is evidence
ofincreased fibrin concentration in tumours compared with normal tissue (O'Meara
and Jackson, 1958). 1311 labelled fibrinogen is said to concentrate in tumours in
both humans and animals (Day, Planinsek and Pressman, 1959a, b; Bale, Spar
and Goodland, 1962 ; Liss, Schmidt and Ernst, 1962 ; Shaeffer, 1963; Monasterio,
Becchini and Riccioni, 1964). The concentration of 131J radioactivity in tumours,
however, may be reduced by deiodination and subsequent equilibration of the 131J
with the iodide pool of the body (Liss et al., 1962). Higher concentrations of
radioactivity in tumours might be obtained if fibrinogen could be labelled with a
different isotope, for example one which was less soluble or diffused less readily.
It has been concluded that niobium isotopes become bound to plasma proteins
because of the observation that the concentration in the blood only decreases
slowly after intravenous injection (Kawin, Copp and Hamilton, 1950; Durbin,
1960). Since there is evidence that tumours tend to concentrate plasma proteins
(Busch, Simbonis, Anderson and Greene, 1956; Babson and Winnick, 1954) a
possible explanation of the high tumour uptake obtained with niobium isotopes
is the binding by plasma proteins. If different plasma proteins could be labelled
with 95Nb it might be possible to influence tumour uptake.
The present paper is an account of a preliminary investigation of the factors
affecting the distribution and tumour uptake of niobium isotopes. Although this
is not yet fully understood and a satisfactory method oflabelling plasma proteins
with 95Nb has not yet been developed, the problems which have arisen may be of
interest to other workers. The tumours used were two transplantable sarcomas
in rats and it is recognised that human tumours may not be similar. However,
for this preliminary work animal experiments are more suitable and the results
can be verified later in human tumours.
METHODS
Isotopes
Two different isotopes of niobium were used, 95Nb and 90Nb, both carrier free
in a solution of 0-5 % oxalic acid. 95Nb was obtained from the RadiochemicalC. M. E. MATTHEWS AND J. M. GARTSIDE
Centre, Amersham, or from Oak Ridge, and 90Nb was made on the cyclotron in this
Unit by bombarding zirconium with deuterons and chemically separating the
90Nb (Sugden, 1964). 95Nb has a half life of 35 days and emits /1 particles (mainly
0*16 MeV7) and y rays of 0-76 MeV. 90Nb has a half life of 14-6 hours and emits
positrons and y rays of various energies.
131J HSA
Human serum albumin (from Lister Institute, fractioni AP2, Kekwick and
MacKay, 1954) was iodinated by the iodine monochloride method (McFarlane,
1958).
Animnals
The rats used were of "Johns' Strain ", derived from a single pair of Wistar
siblings in 1939. Male and female rats from about 200-300 g. were used.
Tuarnours
RIB5. This was a fibrosarcoma which was induced in the strain by Dr. R.
Johns by injection of benzopyrene in 1945.
SBS1.-This was a moderately well differentiated fibrosarcoma with less
necrotic tissue than the RIB5. It developed spontaneously in a rat of the strain
in association with congenital spinabifida.
Both tumours were implanted subcutaneously in the flank as described by
Thomlinson (1960). By this method tumour cells are made into pellets held
together by calcium alginate and the pellets are then tied within the lumen of
small pieces of intestine from a young rat. (For the SBS1 the alginate could be
omitted). This procedure prevents early metastasis, and produces rounded
tumours unattached to skin or muscle whose size can easily be measured externally
with calipers. The growth curve of the RIB5 tumour is given by Thomlinson
(1961). Tumours were allowed to grow to at least 9 mm. in diameter before they
were used.
Procedure
Rats were injected intravenously in the tail with a solution of the isotope in
up to 2 ml. of physiological saline. The solution of the isotope was prepared in
different ways as follows:
Solution (a).- The stock solution of radioactive niobium in 0 5 % oxalic acid
was diluted with saline and the pH was adjusted to 7.4 by adding dilute NaOH,
dropwise.
Solution (b). The stock solution was simply diluted with saline. In this case
the pH was about 1-2.
Solution (c).-The stock solution was diluted with saline and the pH was
adjusted to 4.5.
Solutions (d). Attempts were made to label various plasma proteins by either
incubating the isotope with the protein solution and then dialysing to remove
unbound isotope, or by dialysing the protein solution against saline or citrate
buffer containing the isotope. In both cases about 20 hours at room temperature
were required to obtain maximum labelling as measured by per cent of radio-
activity in trichloracetic acid (TCA) precipitates. However, at 37° C. 2 hours'
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incubation was sufficient. Only about 5 per cent of the total radioactivity finally
became bound to protein. The proportion ofthis which was precipitable by TCA
could be increased by dialysis. Proteins used included human albumin, rat
plasma, and Na2SO4 fractions of rat plasma proteins. The proportion of 95Nb
apparently bound was higher with rat plasma than with any of the fractions.
Only a few experiments using these protein solutions were satisfactory (see results
section), and so the methods are not described in detail.
At different times after injection the rats were anaesthetised with ether, a
blood sample was taken from the heart, the animals were killed and dissected, and
the organs weighed immediately.
Measurement of radioactivity
Radioactivity in rats was measured using a counter consisting of a ring of
G26Pb Geiger tubes with removable lead filters for attenuation. Radioactivity
in organs was measured by sodium iodide crystal scintillation counting; the
large organs were placed between two 1 in. crystals and the small ones in the well
of one of these crystals. Both scintillation and Geiger counters were calibrated
for sources of different volumes, using solutions of the isotopes in water and a
correction for volume and position was applied to each organ measurement.
Positron camera pictures
Pictures ofthe distribution ofradioactivity were taken with a positron camera
(Turner and Freebrey, 1964) using 90Nb. This device, which was invented by
Anger (1963), uses a large sodium iodide crystal scintillation counter in coincidence
with one or more smaller crystals. The source is placed between the crystals,
close to the large one. Pairs of y rays at 180° are produced by annihilation of
positrons, and only those pairs that pass through both crystals give rise to pulses
which are recorded. The position of the flash oflight produced by a y ray in the
large crystal is computed electronically from the relative amount of light falling
on each of the photomultipliers behind this crystal, and a dot is recorded on the
corresponding position on an oscilloscope screen. Thus a dot picture is built up
which shows the distribution of isotope in the source. This is photographed and
the picture obtained enlarged, so that it can be superimposed on a photograph of
the rat.
Paper electrophoresis
Paper electrophoresis was carried out by standard methods using Tris buffer
at pH 7.6, 8-6 and 9.2, and Whatman No. 3 Chromatography paper.
RESULTS
When the 95Nb solution (a) at pH 7-4 was injected, a high uptake was often
found in liver, and this varied considerably in different experiments. A high
liver uptake was never found with isotope solution (b) when free oxalic acid was
not neutralised, nor with solution (c) when it was partly neutralised to pH 4*5.
It seems likely that when all the oxalic acid is neutralised a colloidal solution is
formed which is taken up by the reticuloendothelial [system. Schubert and Conn
(1949) discuss the colloidal properties of some fission products and they find that
oxalic acid prevents formation of a colloidal solution of carrier free 95Nb. After
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the first few experiments, therefore, the isotope solution was always adjusted to
pH 4*5 before injection.
The distribution in organs at different times after injection is shown in Table I
for rats with SBS1 tumours. Some results obtained with 1311 labelled human
TABLE I.-Uptake ofIsotope in Rat Organs After
Intravenous Injection (% dose g.)
95Nb pH 4 5 131I HSA
Hours . 12 6 1 24-5 30 47 72 3 96 4 . 24 3
Number of rats. . 2 2 10 1 2 3 2 . 4
Tumour . . 143 176 2 07 215 174 1 42 1 31 0 690
Plasma . 104 435 323 2 31 1 83 1 19 0 589 202
Blood . 526 226 1 70 164 144 0(633 0 346 113
Spleen . . 093 106 217 2 78 158 339 327 . 0201
Kidney . 129 105 1 76 2 51 2 29 260 2 73 . 0306
Liver . . 0517 0 517 0 489 0 745 0 533 0-583 0 583 . 0 226
Lymph nodes . . 103 0-927 1-36 1P41 1P47 1P92 1P57 0281
Marrow (I femur) . 1 75 2 75 1 89 1 47 2 75 1P90 . 0-282
Bone +marrow (I femur). 0 452 0 325 1 06 1P06 0 889 1.11 1P20 . 0148
Lungs . . 153 144 0777 0-878 0 657 0 683 0 925 0704
Intestine . 0 284 0 261 0 210 0 302 0-224 0 192 0-151 . 0312
Muscle . 0(217 0 201 0 211 04173 0 208 04171 04158 0108
Skin. . . 0(297 0-341 0 401 0 444 0 331 0-521 0-354 . 0363
Brain . . 0201 0-0950 0 0765 0 0775 0 0504 0 0384 0 0287 00456
Testes . 0467 0 618 0 761 0-955 0 818 0 614 0 782 . 0267
Figures expressed as % dose.
Blood1 . 896 410 294 312 165 108 5 07 20 5
MUScle2 . 236 235 2341 21 1 23 3 18 9 14 9 12 6
Skin. 116 147 15 6 17 1 13 6 14 8 121 166
Liver 461 454 404 537 4 14 4-46 410 186
Kidneys 207 2-38 288 400 3 53 3 99 389 0553
Intestine . 464 4 80 3 52 4 28 3 36 2 66 207 478
Tumour . 171 165 249 294 225 2 79 2 44 107
Whole body . 995 887 892 908 81 1 70 3 64-5 . 638
1 Taking blood volume as 7%01 body weight.
2 Taking muscle mass as 45% body weight, (Caster, Poncelet, Simon and Armstrong, 1956).
Radioactivity in organs includes that due to the blood in each organ.
serum albumin are also shown for comparison. The distribution of radioactivity
in the different organs is similar for 95Nb and 131J HSA, although excretion is less
for 95Nb so that concentrations tend to be higher than for 131I. In tumour,
spleen, kidney, lymph nodes and bone marrow, 95Nb concentrations are con-
siderably higher than 1311 concentrations. The variation of concentration of
radioactivity with time is shown in Fig. 1 for plasma and whole body, and in Fig. 2
for tumour, spleen and kidney. For other organs the concentrations were approxi-
mately constant up to about 96 hours, or else fell slightly.
Table II shows tumour uptakes at about 24 hours after injection for SBS1
and RIB5 tumours of different weights. SBSi tumours probably show some
decreased uptake with increasing tumour size. Although there may be a similar
effect with RIB5 tumours, there is much greater variation in tumour concentration
of niobium.
When solutions (d) were injected, that is, protein solutions in which the 95Nb
was partly precipitable with TCA, high uptakes were sometimes found in liver,
spleen or lungs, probably again due to formation of a colloidal solution. In other
cases the distribution in the various organs did not differ significantly from resultsTUMOUR IJPTAKE OF NIOBIUM ISOTOPES
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FIG. 1. Variation ofwhole body and plasma 95Nb radioactivity with time after intravenous injection.
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FIG. 2.-Variation of 95Nb concentration in tumour, spleen and kidney with time after intravenous
injection.
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TABLE II.-Tumour 95Nb Concentrations (pH 4.5) at 24 Hours
SBS I RIB 5
Weight 0o dose/g. Weight % dose/g.
0-678 2-32 0-96 3-28
0-801 1-69 . 1-02 1-28
0-814 1-95 109 1-17
1-08 2-08 . 1-51 1-iO
1-18 2-01 . 1-69 4-86
12-3 2-57 2-15 1-86
1-31 1-88 2-70 1-88
1-33 2-29 4-10 1-47
1-47 2-13 4-70 1-84
2-15 1-87 4-77 2-21
3-61 1-00 . 4-94 1-27
3-68 0-90 . 13-7 1-36
4-57 1-710
4-59 1-03
5-07 1-03
5-41 1-05
10-6 0-978
shown in Tables I and II, so that it is doubtful if 95Nb was really protein bound.
TCA precipitation ofplasma samples taken at different times after intraperitoneal
injection indicated that from 60 to 80 % of 95Nb was protein bound.
Fig. 3 shows a picture of 90Nb distribution in a rat with an RIB5 tumour taken
with the positron camera. It was found that the tumour could be clearly seen if
it contained at least 10 % of the radioactivity in the whole animal; this corres-
ponds to a tumour of about 15 mm. in diameter.
Paper electrophoresis was carried out in an attempt to investigate which
protein binds 95Nb but results were inconclusive under the conditions used since
95Nb alone moved to the same position as the plasma proteins, and a broad peak
of radioactivity was obtained, so that it was impossible to determine whether the
isotope was in fact bound to protein or not.
DISCUSSION
The similar distribution of 95Nb and 131I labelled plasma proteins indicates
that niobium isotopes probably do become protein bound after injection. How-
ever, this is difficult to prove conclusively since paper electrophoresis cannot be
used, unless a more suitable buffer or type of paper can be found. Also protein
precipitation methods may not give reliable results owing to the possible formation
of a colloidal solution of 95Nb which may be carried down with the protein precipi-
tate. At short intervals after injection much of the radioactivity in organs will
be due to their blood content. In an earlier series of experiments this blood
radioactivity was subtracted and the extravascular radioactivity was obtained
(Matthews and Molinaro, 1963) ; results were similar for 95Nb and 1311 HSA.
Most of the extravascular 95Nb is in muscle and skin just as for 131I labelled
albumin (Matthews, Bruce-Robertson and Humphrey, 1962). The plasma
radioactivity curve for 95Nb is also similar to that obtainedwith1311 labelled plasma
proteins (Campbell, Cuthbertson, Matthews and McFarlane, 1956; Cohen, 1957),
EXPLANATION OF PLATE.
FIG. 3. Distribution of 90Nb in a rat bearing an RIB5 tumour taken with the positron camera.
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and the biological half life is close to that of 1311 labelled fibrinogeni or alpha
globulin. The initial fall in plasma radioactivity seems to be rather more rapid
with 95Nb than with 131J proteins but there are too few measurements to indicate
whether this is really a significant difference. When plasma samples were
fractionated by sodium sulphate precipitation, the TCA precipitable radioactivity
was divided between albumin and y globulin fractions; both these fractions would
contain some alpha globulin. The fibrin clot, however, contained very little
radioactivity. It seems possible, therefore, that 95Nb may become bound to
alpha globulin, but more experiments are needed to confirm this.
The 95Nb radioactivity which leaves the plasma is not all excreted (Fig. 1)
but is partly taken up by the organs, so that organ/plasma concentration ratios
increase with time. For most organs the absolute concentration decreases slightly
with time, but for kidney and spleen there is a pronounced rise up to 96 hours
after injection for kidney and up to about 48 hours for spleen. This rise is roughly
parallel to the excretion curve of 95Nb, as shown in Fig. 4 where spleen and kidney
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uptakes are plotted as percentage dose. This seems to indicate either that after
protein catabolism 95Nb is released in a form which is taken up by spleen and
kidney, or possibly that the plasma protein concerned is catabolised in these
organs.
Tumour 95Nb concentration rises during the first 24 hours after injectioni and
then falls. The fall in concentration seems to be merely a reflection ofthe growth
of the tumour since the percentage dose remains approximately constant. The
higher 24 hour uptake for some small tumours (Table II) might possibly be due
to the effect of inflammation after the transplantation as observed by Day et al.
(1959b), although the interval between implantation and injection was never less
than about 10 days whereas Day et al. found increased 131J fibrinogen uptake due
to inflammation for only about 5 days after implantation. For large tumours the
uptake is similar for RIB5 and SBS1 tumours.
For investigation of tumour uptake in patients 90Nb has advantages over 95Nb
since its short halflife enables a larger number ofmc to be given for the same radia-
tion dose and also pictures of the distribution can be taken with the positron
camera. However, iftumour uptake is to be followed for longer times, more 90Nb
must be given and then radiation dose is lower with 95Nb.
Much more work is required before 95Nb metabolism and tumour uptake is
fully understood and this paper is intended to indicate some ofthe interesting lines
of investigation which may give information about plasma protein metabolism
as well as about tumour uptake.
SUMMARY
The distribution of carrier free niobium isotopes in rats and uptake in two
different transplanted rat sarcomas is described. Factors affecting this distribu-
tion, including binding to plasma proteins, are discussed. The investigation is
complicated by the fact that niobium isotopes readily form colloidal solutions.
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